



Contributed Presentation



Normalization Methods and Statistical Inference to Identify Differentially Expressed MicroRNAs with an Application to a Residential Cohort Exposed to Environmental Toxins and Pollutants





Authors

- Christina Pinkston, MS University of Louisville
- Matthew Cave, PhD University of Louisville
- Brian Chorley, PhD USEPA
- Shesh Rai, PhD- University of Louisville

Disclosures and Disclaimer

The authors declare they have no actual or potential competing financial interests. Findings presented here are those of the authors and do not necessarily represent the official position of USEPA, UofL, ATSDR, or NIH.











Acknowledgments


- Linda Birnbaum (NIEHS/NIH)
- Marian Pavuk (ATSDR/CDC)
- USEPA: Gleta Carswell and Gail Nelson
- UofL: Banrida Wahlang, Youssef Saad, and Kimberly Head
- Investigators who measured biomarkers, including Andreas Sjödin, Richard Jones, Frank Middleton, Paula Rosenbaum, Heather Clair.

Funding

This research was supported, in part, by the National Institute of Environmental Health Sciences (R35ES028373, R01ES032189, T32ES011564, P42ES023716, P30ES030283 and R21ES031510 and the Intramural Research Program Z01-ES100475); the Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention (200-2013-M-57311);and the Wendell Cherry Endowed Chair. The Anniston Community Health Survey original data collection was funded by the Agency for Toxic Substances and Disease Registry (5U50TS473215).


Study Aims

Aim 1: Determine the best normalization strategy for microRNAs (miRs) profiled using the Fireplex® platform technology by Abcam.





Study Aims



Aim 2: Identify
differentially
expressed
hepatotoxicity miRs
in a cohort exposed
to polychlorinated
biphenyls (PCBs).






Anniston Community Health Study I (Anniston, Alabama; 2005-2007)

- Participants lived near a former Monsanto Chemical Corporation plant where PCBs were manufactured until 1971 [1]
- Fasting blood draws were collected on all participants [1]
- Liver biomarkers were measured by the Cave Laboratory [2]
- 60% show signs of liver disease (>200 U/L Keratin 18-M30 (K18-M30) and/or >300 U/L K18-M65) [2]
- Primary covariates of interest: Age, Sex, Race, and BMI; most differ by liver disease status
- PCBs were whole weight, measured by NIEHS, and adjusted for total lipids in the models [1]
- IRB-approved (University of Louisville) [2]









MicroRNAs (miRs)



Profiling Technology

Targeted miRs - small, single-stranded noncoding RNA [3] - were measured in serum by FirePlex® technology by Abcam [4]

Pros of the current profiling technology

- Allows profiling of limited serum samples not possible with other technologies
- Profile up to 68 miRs simultaneously with lower cost than other technologies

Cons of the current profiling technology

- Detection of low abundance miRs is reduced and has greater variability [5]
- There were no housekeeping miRs included to use for normalization

Normalization Procedures

For this talk, we compare fold change of differentially expressed miRs from the following data:

- 1. Unnormalized (raw, background subtracted) expression values
- 2. **geNorm**: Software provided [6, 7]
- 3. Quantile Normalization: Overall [8]
- 4. Quantile Normalization: by liver disease class [9]



Differential Expression

Modeling to find the least-square mean estimates by group:

- Log-10 transform the raw, background subtracted miR expressions
- Model includes: age, self-reported sex, self-reported race, BMI, total PCBs, total lipids

$$\begin{split} log_{10}\big(miR_{(i)}\big) = & \ \alpha_{(i)} + \beta_{1(i)} * Liver \ Disease_{Necrotic} + \beta_{2(i)} * Liver \ Disease_{Other} + \\ & \gamma_{1(i)} * Self - reported \ Race_{NHW} + \gamma_{2(i)} * Sex_{Female} + \gamma_{3(i)} * Age + \\ & \gamma_{4(i)} * BMI + \gamma_{5(i)} * log_{10}(total \ lipids) + \gamma_{6(i)} * assayPlate + \\ & \gamma_{7(i)} * log_{10}\left(\sum PCBs\right) + \varepsilon_{(i)} \end{split}$$

$$FC_{j(i)} = 10^{[\beta_{j(i)}]}$$

$$SE(FC_{j(i)}) = 10^{[\beta_{j(i)}]} * ln(10) * SE(\beta_{j(i)})$$
(Eq 2)
(Eq 3)



Differential Expression

Fold change of Liver Disease vs. No Liver Disease

• Mean and variance are estimated as shown in [10]

$$\widehat{\theta_{(i)}} = e^{(ln(10)*LSM_{(1i)} + \frac{ln(10)^2*S_{LSM_{(1i)}}^2 - ln(10)*LSM_{(0i)} - \frac{ln(10)^2*S_{LSM_{(0i)}}^2}{2})}$$
(Eq 4)

$$log(\widehat{\theta_{(i)}}) = ln(10) * LSM_{(1i)} + \frac{ln(10)^2 * S_{LSM_{(1i)}}^2}{2} - ln(10) * LSM_{(0i)} - \frac{ln(10)^2 * S_{LSM_{(0i)}}^2}{2}$$
(Eq 5)

$$\widehat{Var}\left(\widehat{log(\theta_{(i)})}\right) = \frac{\ln(10)^2 * S_{LSM_{(1i)}}^2}{n_1} + \frac{\ln(10)^4 * S_{LSM_{(1i)}}^4}{2(n_1 - 1)} + \frac{\ln(10)^2 * S_{LSM_{(0i)}}^2}{n_0} + \frac{\ln(10)^4 * S_{LSM_{(0i)}}^4}{2(n_0 - 1)} (Eq 6)$$




Differential Expression

Find confidence interval estimates [11]

- We construct the 95% confidence interval for $\log(\theta)$ using t instead of z
- Scale this to θ by taking the anti-logs


$$log(\widehat{\theta}_{(i)}) \pm t_{0.95,n_0+n_1-2} * \sqrt{\widehat{Var}(log(\widehat{\theta}_{(i)}))}$$
 (Eq 7)






Performance by Normalization Technique and Fold Change Equation

We display selected miRs from our sample. We show the four methods of normalization: None, geNorm, Quantile Normalization Overall (QNorm), and Quantile Normalization by class (QNormC). Two methods of fold change (FC) calculation are shown: the anti-log of the beta coefficient, and the derived Fold change based on the log-normal distribution.







Summary of Findings

- We recommend quantile normalization by class/group, especially when the groups are unbalanced
- It may be beneficial to compare different fold change calculations to compare the different underlying responses (i.e. mean vs. median)



References

- 1. Pavuk M, Olson JR, Sjödin A, et al. (2014) Science of The Total Environment. 473-474:286-297
- 2. Clair HB, Pinkston CM, Rai SN, et al. (2018) *Toxicological Sciences* 164(1):39-49
- 3. Lee RC, Feinbaum RL, Ambros V. (1993) Cell 75:843-854
- 4. Tackett MR, Diwan I. (2017) Methods in Molecular Biology 1654:209-219
- 5. Godoy PM, Barczak AJ, DeHoff P, et al. (2019) Cell Reports 29:4212-4222
- 6. FirePlex Analysis Workbench User Guide (2017)
- 7. Vandesompele J, De Preter K, Pattyn F, et al. (2002) *Genome Biology* 3(7):research0034.1–0034.11
- 8. Bolstad BM, Irzarry RA, Astrad M, et al. (2003) Bioinformatics 19(2):185-193
- 9. Zhao Y, Wong L, Goh WWB. (2020) Scientific Reports 10:15534
- 10. Olsson U. (2005) Journal of Statistics Education 12(1)
- 11. Zhou XH, Gao S. (1997) Statistics in Medicine 16:783-790



